MSD has entered a definitive agreement to acquire Caraway Therapeutics in a deal worth up to $610m.
MSD will acquire the Massachusetts-based small molecule therapeutics company through one of its subsidiaries. The $610m consideration includes undisclosed upfront and milestone-based payments. MSD plans to expense the upfront payment as part of its Q4 2023 expenses, as per a 21 November .
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMSD has been a Caraway shareholder through its subsidiary, MRL Ventures Fund. As per the agreement, the company will 鈥渁cquire all outstanding shares of Caraway with earnout milestones associated with the development of certain pipeline candidates鈥�. The transaction has already been approved by Caraway鈥檚 board of directors.
Caraway has a preclinical pipeline of therapies for neurogenerative diseases, especially . Caraway鈥檚 lead preclinical candidate targets the transient receptor potential cation channel subfamily (TRPML1), which is located on lysosomes and regulates their enzymatic activity. As lysosomal dysregulation has been seen in lysosomal storage and neurodegenerative diseases, the compound is being evaluated as a treatment for the lysosomal storage disorder, Gaucher disease, and glucocerebrosidase (GBA)-mutated Parkinson鈥檚 disease.
Caraway has previously received from the Michael J. Fox Foundation for Parkinson鈥檚 research to explore the role of TRPML1 in the condition, the most recent of which was awarded in January 2022. Parkinson鈥檚 disease market is forecasted to generate $6.3bn in global sales in 2029, as per GlobalData analysis.
As per GlobalData, one of the highest-grossing therapies in the field is expected to be AbbVie鈥檚 drug-device ABBV-951 (foscarbidopa/foslevodopa), which delivers a subcutaneous continuous infusion of levodopa. In March, the US Food and Drug Administration (FDA) requested before making any decision regarding ABBV-951鈥檚 new drug application.
GlobalData is the parent company of 色界吧 Technology.
In the last few months, MSD has invested considerable resources in expanding its therapeutics portfolio through acquisitions and partnerships. In October, the company signed a licensing agreement with Daiichi Sankyo to develop and commercialise three antibody-drug conjugate (ADC) candidates. The US biologics licence application (BLA) submission for one of the licensed ADCs, patritumab deruxtecan, is planned for March 2024.
In June, the company acquired Prometheus Biosciences for approximately $10.8bn. The acquisition expanded MSD鈥檚 immunology pipeline with Prometheus鈥� lead clinical candidate, PRA-023.
